AstraZeneca (AZN), Pfizer (PFE) and Novartis (NVS) are among the suitors preparing bids for Onyx Pharmaceuticals (ONXX), Bloomberg reports, citing two people familiar with the matter. First round bids may come this week, while Amgen (AMGN) remains interested in bidding and is waiting to hear from Onyx about resuming talks, the report adds. Shares of Onyx are up 3% to $130.11 following Bloomberg's story.
Futures fell on reports of Iran explosions: The market power trend is about to end. Netflix gave weak guidance.
The S&P 500 could bottom out in the next month, according to Fundstrat's head of research Tom Lee.
(Bloomberg) -- Global markets were rocked by reports of fresh conflict in the Middle East that sent stocks lower while oil and haven assets including Treasures and the dollar rallied.Most Read from BloombergElon Wants His Money BackDubai Grinds to Standstill as Flooding Hits CityRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingSingapore Loses ‘World’s Best Airport’ Crown to QatarRed Lobster Considers Bankruptcy to Deal With Leases and Labor CostsGains for Treasuries sent the 10-y
Trump Media is advising investors on ways to prevent their shares from being loaned for a short-interest position.
The insurer was accused by a short-seller of "extensive" fraud.
Wall Street's most-prominent stock-split stock of 2024 has been purchased on three separate occasions by a lawmaker who completed over 4,200 trades last year.
In the chaos of the 2008 recession, perhaps no bank stood more prepared than Jamie Dimon's J.P Morgan Chase & Co. (NYSE:JPM). In advance of the crisis, Jamie Dimon realized that "underwriting standards were deteriorating across the industry," with late payments on subprime loans rising. In late 2006, the bank led his firm to exit Wall Street's hot subprime business, starting with a frantic call made to J.P. Morgan's vacationing Chief of Securitized Products where he said, "I really want you to w
An FAQ on the Truth Social owner’s website gave stockholders multiple ways to avoid their shares being lent to short sellers.
Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?
Her flagship Ark Innovation ETF has lost 18% this year.
